Skip to main content
. 2022 Oct 9;10(1):53–70. doi: 10.1007/s40744-022-00498-x

Fig. 4.

Fig. 4

CFB in mTSS among patients with four PPFs or fewer than four PPFs. *P < 0.05 versus PBO at W24 or versus ADA at W52. **P < 0.01 versus PBO at W24 or versus ADA at W52. All treatment groups also received methotrexate. ADA adalimumab, CFB change from baseline, FIL100 filgotinib 100 mg, FIL200 filgotinib 200 mg, mTSS modified total Sharp score, PBO placebo, PPF poor prognostic factor, W week